You can read the study that finds evidence of antibody dependent enhancement (of disease) in Frontiers journal. I’ve been compiling such evidence in this answer:
What Makes the ModRNA COVID19 Vaccines So Effective
The single center study of patients suffering with acute respiratory failure in general and admitted to Ohio State University hospital (n = 152) and from COVID19 disease in particular (n = 112) found that of the 43 non-vaxxed patients and 23 vaxxed patients admitted between the December 2020 rollout and November 2022 the latter had nearly twice the mortality rate (70%) as the former (37%).
Complete primary series recipients also suffered increased mortality compared to patients who had received only the first dose. The study also found that non-vaxxed patients with comorbidities had higher SARS-CoV-2 specific antibodies levels compared to their vaxxed counter parts which suggests that comorbidities are not the only cause of decreased antibody response.
Among the patients admitted for non-COVID19 acute respiratory failure (n = 40) the vaxxed patients had a slightly lower mortality rate (27%) than the unvaxxed patients (36%) which given the small sample size isn’t statistically significant but shows that the 6 year median age gap and higher comorbidity index score among vaxxed patients does not explain the mortality difference between vaxxed and unvaxxed patients and even the authors note:
CCI or age may not be sufficient to stratify risk, as even when patients with similar CCI/age were compared, we still observed significantly (p=0.02) improved survival in NVax patients.
The only other possible explanation is that the hospitalized vaxxed patients received their last dose at least 4 months if not 6 months or more before infection. As I have noted in prior answers this is when the Immunoglobulin G subclass switch starts to unfold in modRNA recipients whose supposed increased protection exists only on a very short timeline that doesn’t last an entire calendar year. Unlike most government funded studies that try to support the safe and effective narrative by only measuring risk differences 4 or 5 but no more than 6 months since the latest dose this University study compared risks over a two year period. Studies that have measured annual mean VE (against hospitalization) have found abysmal results with estimated risk reduction quickly tanking after 4 months, becoming negligible at 6 months and often negative (i.e. increased risk) after 6 months. CDC observational research found that mean VE against hospitalization for children and adolescents is estimated at 25% between 4 months to 364 days out with a lower limit of negative 9%.
CDC Confirms modRNA VE is Abysmal After 4 months
A WHO funded study in Eastern Europe found that annualized VE against hospitalization was 15% for adults and a negligible 5% for adults 60 years or older and once again confirmed that the increased protection only appeared in the first 4–5 months becoming negligible by 6 months and even negative between 9–12 months after the last dose.
Sloppy and Cohort Bias WHO funded study finds annual VE of 15%
It is not inconceivable that researchers would find even worse results over two years instead of one since most vaxxed patients stopped with the primary series or first booster and go a year or more between doses after the first three doses.